Combined modality therapy of cT2N0M0 esophageal cancer : The University of Texas M. D. Anderson Cancer Center experience (pages 925–930)
Panteleimon Kountourakis, Arlene M. Correa, Wayne L. Hofstetter, Jeffrey H. Lee, Manoop S. Bhutani, David C. Rice, Ritsuko Komaki, Dipen M. Maru, William A. Ross, Ara Vaporciyan, Stephen G. Swisher and Jaffer A. Ajani
Article first published online: 19 OCT 2010 | DOI: 10.1002/cncr.25651
Data from 49 patients treated with preoperative chemoradiation were analyzed. Pathologic complete response was observed for 19 (39%) patients. The 10-year actuarial overall survival (OS) for adenocarcinoma patients was >60%. In the multivariate analysis for OS, smoking was found to be an independent prognosticator (P = .02). In the multivariate analysis for disease-free survival (DFS), advanced pathologic stage (P = .05) and lymph node metastases (P = .006) were independent prognosticators. Patients with adenocarcinoma (P = .002) and those with pathologic N0 disease had better OS and DFS. Trimodality therapy should be prospectively compared with primary surgery in these patients.